acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (aβo) in synaptic dysfunction and neurodegeneration. these early insights have fostered decades of research on the biology of aβo at acumen and throughout the field. we are now on the on cusp of realizing the therapeutic potential of aβo targeted drugs.
Company profile
Ticker
ABOS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
ABOS stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
5 Jun 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
14 May 24
EFFECT
Notice of effectiveness
25 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
S-3
Shelf registration
27 Mar 24
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
Transcripts
ABOS
Earnings call transcript
2024 Q1
14 May 24
ABOS
Earnings call transcript
2023 Q4
26 Mar 24
ABOS
Earnings call transcript
2023 Q3
13 Nov 23
ABOS
Earnings call transcript
2023 Q2
8 Aug 23
ABOS
Earnings call transcript
2023 Q2
8 Aug 23
ABOS
Earnings call transcript
2023 Q1
9 May 23
ABOS
Earnings call transcript
2022 Q4
27 Mar 23
ABOS
Earnings call transcript
2022 Q3
15 Nov 22
ABOS
Earnings call transcript
2022 Q2
16 Aug 22
ABOS
Earnings call transcript
2022 Q1
17 May 22
Latest ownership filings
4
Peter Kolchinsky
10 Jun 24
4
Jeffrey L. Ives
10 Jun 24
4
Laura Stoppel
10 Jun 24
4
John A Stalfort III
10 Jun 24
4
Derrell Porter
10 Jun 24
4
Nathan B Fountain
10 Jun 24
4
Kimberlee C Drapkin
10 Jun 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
FRANKLIN RESOURCES INC
6 Feb 24
4
James J. Doherty
1 Feb 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.16 mm | 47.16 mm | 47.16 mm | 47.16 mm | 47.16 mm | 47.16 mm |
Cash burn (monthly) | 6.65 mm | 2.57 mm | 5.92 mm | 5.48 mm | 5.95 mm | 4.23 mm |
Cash used (since last report) | 25.71 mm | 9.93 mm | 22.90 mm | 21.19 mm | 23.01 mm | 16.35 mm |
Cash remaining | 21.45 mm | 37.23 mm | 24.26 mm | 25.97 mm | 24.15 mm | 30.82 mm |
Runway (months of cash) | 3.2 | 14.5 | 4.1 | 4.7 | 4.1 | 7.3 |
Institutional ownership, Q1 2024
7.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 9 |
Closed positions | 34 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 2.86 bn |
Total shares | 4.45 mm |
Total puts | 76.70 k |
Total calls | 241.60 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Paul B Manning | 2.55 mm | $0.00 |
Sands Capital Ventures Discovery Fund III | 1.15 mm | $23.15 mm |
Susquehanna International | 265.84 k | $1.08 bn |
TD Asset Management | 148.80 k | $602.64 mm |
New York Life Investment Management | 95.09 k | $385.11 mm |
Catalyst Financial Partners | 89.70 k | $311.26 mm |
Susquehanna Fundamental Investments | 62.52 k | $253.20 mm |
Gsa Capital Partners | 25.37 k | $103.00 k |
Susquehanna Portfolio Strategies | 21.90 k | $88.71 mm |
Pinnacle Associates | 18.02 k | $72.98 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Jun 24 | Drapkin Kimberlee C | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |
10 Jun 24 | Nathan B Fountain | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |
10 Jun 24 | Derrell Porter | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |
10 Jun 24 | Sean Stalfort | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |
10 Jun 24 | Laura Stoppel | Stock Option Common Stock | Grant | Acquire A | No | No | 2.62 | 25,000 | 65.50 k | 25,000 |
News
Citigroup Initiates Coverage On Acumen Pharmaceuticals with Buy Rating, Announces Price Target of $7
25 Jul 24
Acumen Pharmaceuticals To Present Patient Experience And Biomarker Insights From Phase 1 INTERCEPT-AD Study At The Alzheimer's Association International Conference 2024
11 Jul 24
Halozyme's ENHANZE Product Gets New Patent Grant in EU
6 Jun 24
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
15 May 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
14 May 24